DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Kudo M, Finn RS, Qin S. , et al.
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Lancet 2018;
391 (10126): 1163-1173
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.